EQRx IPO
EQRx was a biotechnology company focused on developing innovative medicines at radically lower prices through a new approach to drug pricing and development. The company aimed to make high-quality medicines accessible globally by reimagining the traditional pharmaceutical business model.
What We Know
EQRx went public via SPAC merger in January 2022, trading under ticker EQRX on NASDAQ. The company raised significant capital but struggled with its business model and market reception. In December 2023, EQRx announced it would be acquired by Aumni Pharmaceuticals in an all-stock deal, effectively ending its brief tenure as a public company. The acquisition represented a significant decline from its initial public market valuation.
Frequently Asked Questions
Has EQRx had an IPO?
Yes, EQRx had a brief public trading period after going public via SPAC in January 2022. However, the company was acquired by Aumni Pharmaceuticals in December 2023.
When is the EQRx IPO date?
EQRx already completed its public market debut in January 2022 but was subsequently acquired. The company is no longer independently publicly traded.
How can I buy EQRx stock?
EQRx stock is no longer available for purchase as the company was acquired by Aumni Pharmaceuticals in 2023. The original EQRX ticker is no longer active on public exchanges.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts